Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003444 · ClinicalTrials.gov registry record · Phase 3
Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 167
- Enrollment target
NCT00003444 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 167 participants.
The verdict
NCT00003444, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 167 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Interferon alfa-2b may interfere with the growth of cancer cells. It is not yet known whether giving radiation therapy with interferon alfa-2b is more effective than giving interferon alfa-2b alone in treating melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus interferon alfa-2b with that of interferon alfa-2b alone in treating patients who have melanoma that has metastasized to lymph nodes in the neck, under the arm, or in the groin.
Interventions
- RADIATION radiation therapy
- BIOLOGICAL recombinant interferon alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 1999-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003444
The ClinicalTrials.gov registry entry for NCT00003444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which radiation therapy is the first listed.
NCT00003444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003444 about?
NCT00003444 is a clinical study titled "Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Interferon alfa-2b may interfere with the growth of cancer cells. It is not yet known whether giving radiation therapy with interferon alfa-2b is more effective than giving interferon alfa-2b alone in treating melanoma. PUR...
What is the current status of trial NCT00003444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 167 participants. The study started on 1999-03-29.
What interventions are being tested in trial NCT00003444?
The interventions under investigation include: radiation therapy (RADIATION), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003444?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.